Petra Hegmann, Author at MC Services corporate website

-1

archive,author,author-petra-hegmann,author-9,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.7.0,vc_responsive

HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy

InflaRx Awarded up to EUR 43.7 Million (~USD 50.7 Million) Grant by German Government to Advance the Development of Vilobelimab for Treatment of Severe COVID-19

MagForce AG: MagForce USA, Inc. has Received FDA’s Conditions for Approval of the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19

APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

XPhyto Reports Development Update for its Drug Delivery Business

Marinomed Biotech AG signs financing agreement with Nice & Green S.A. to advance its scientific and clinical programs

Secarna Pharmaceuticals announces publication of new preclinical data showing strong potential of LNAplus™-based ASOs to effectively treat diabetic kidney disease

RedHill Biopharma Reports Further Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

MagForce AG and CHIP Hospital Málaga Announce Collaboration Agreement for the Commercial Treatment of Glioblastoma Cancer Patients with the NanoTherm Therapy System in Spain